Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Lenny Dang, David W. White, Bryson D. Bennett et al. · Nature · 2009 · 4K citations · Full text

Tumor Biology, Cancer-associated Idh1 Mutations, Oncogenic Agent +4

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

Wei Xu, Hui Yang, Ying Liu et al. · Cancer Cell · 2011 · 2.8K citations · Full text

Molecular Pharmacology, Aldehyde Dehydrogenase, Biochemistry +4

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

María E. Figueroa, Omar Abdel‐Wahab, Chao Lü et al. · Cancer Cell · 2010 · 2.7K citations · Full text

Hematological Malignancy, Somatic Variant, Hypermethylation Phenotype +10

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.6K citations

Mixed-phenotype Acute Leukemia, Pathology, Acute Leukemia +18

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

Elaine R. Mardis, Li Ding, David J. Dooling et al. · New England Journal of Medicine · 2009 · 2.2K citations · Full text